Blood factor monitoring assay and uses thereof
AssigneeBioverativ Therapeutics Inc.
InventorJurg SOMMER
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and compositions for diagnosing and treating subject having a bleeding disorder. The disclosed methods comprise contacting a sample, e.g., a blood or plasma sample obtained from the patient, with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate. Also provided is a global hemostasis test based on the integration of clotting time (Ct) and pharmacokinetics data. The methods and compositions presented can be applied to point-of-care diagnostic systems.
Claims25
A composition for the measurement of coagulation factor activity in a sample comprising an activated coagulation factor and a phospholipid mixture, wherein the composition is dried onto a solid substrate.
2-4. (canceled)
6-13. (canceled)
(canceled)
21-28. (canceled)
32-43. (canceled)
A method for determining a coagulation factor level in a bleeding disorder patient, comprising:
- (a) contacting a sample obtained from the patient with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate;
- (b) measuring the time between the contacting of the activation mixture with the sample and the onset of clotting, thereby calculating the clotting time (Ct);
- and,
- (c) correlating the Ct value with the level of coagulation factor in the sample.
46-83. (canceled)
89-108. (canceled)
Dependencies are inferred from the claim text.